4BKT image
Deposition Date 2013-04-29
Release Date 2013-11-27
Last Version Date 2024-10-16
Entry Detail
PDB ID:
4BKT
Title:
von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with (2S,4R)-N-methyl-1-[2-(3-methyl-1,2-oxazol-5-yl)ethanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
Biological Source:
Source Organism:
HOMO SAPIENS (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.35 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 41 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:TRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 2
Gene (Uniprot):ELOB
Chain IDs:A, D, G, J
Chain Length:104
Number of Molecules:4
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Molecule:TRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 1
Gene (Uniprot):ELOC
Chain IDs:B, E, H, K
Chain Length:97
Number of Molecules:4
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Molecule:VON HIPPEL-LINDAU DISEASE TUMOR SUPPRESSOR
Gene (Uniprot):VHL
Chain IDs:C, F, I, L
Chain Length:162
Number of Molecules:4
Biological Source:HOMO SAPIENS
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CAS A CYS S-(DIMETHYLARSENIC)CYSTEINE
Primary Citation
Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?
Acs Med.Chem.Lett. 5 23 ? (2014)
PMID: 24436777 DOI: 10.1021/ML400296C

Abstact

Modulation of protein-protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose significant challenges to fragment binding detection. Here, we investigate the requirements for ligand-based NMR techniques to detect rule-of-three compliant fragments that form part of known high-affinity inhibitors of the PPI between the von Hippel-Lindau protein and the alpha subunit of hypoxia-inducible factor 1 (pVHL:HIF-1α). Careful triaging allowed rescuing weak but specific binding of fragments that would otherwise escape detection at this PPI. Further structural information provided by saturation transfer difference (STD) group epitope mapping, protein-based NMR, competitive isothermal titration calorimetry (ITC), and X-ray crystallography confirmed the binding mode of the rescued fragments. Our findings have important implications for PPI druggability assessment by fragment screening as they reveal an accessible threshold for fragment detection and validation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures